ARS Pharma narrows commercial focus for neffy, sees CSU data in Q1 2027
The company reported $26.2 million in Q2 2026 neffy revenue, named a new commercial chief, and pointed to interim urticaria trial data expected in early 2027.
SEC filing
Latest
3 stories
Thursday, August 13
Friday, July 17
ARS Pharmaceuticals board member resigns, chief medical officer departs
Richard Lowenthal left the board and Sarina Tanimoto exited as chief medical officer on July 15, 2026, with both receiving additional cash payments tied to severance terms.
SEC filing